STAT NewsDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 07:17:13·⟳ 抓取 07:19:46 +2m33s·⚡ 决策 10-27 17:12:41 +9h52m·9.5 小时前
STAT通讯回顾罗氏divarasib ESMO三期数据：KRAS G12C肺癌头对头优效，属已充分传播的旧催化重述
本条STAT News通讯是对2026-10-25 ESMO主席研讨会已公布、并同步NEJM发表的Krascendo 1完整数据的会议回顾；顶线阳性结果更早在2026-07-02已公告。同一催化在过去约24小时内已被GlobeNewswire通稿、FierceBiotech、Bloomberg、RTTNews、格隆汇等多源报道，本臂此前已至少四次判定不做。本条不含任何新增数据、监管节点或商业化事实，无剩余edge。
📄 原文STAT News↗ 原文
STAT+: Roche gets a lung cancer win with its KRAS drug divarasib
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wa…
不做 罗氏(Roche)（RHHBY.US）
旧催化重述无新增事实（顶线2026-07-02、完整数据2026-10-25 ESMO/NEJM），已充分price-in；超大盘药企单一峰值10–20亿瑞郎管线弹性小，OTC ADR流动性差，无剩余edge
不做 安进(Amgen)（AMGN.US）
Lumakras头对头落后的竞争利空随7月与10-25数据已消化，收入占比小，本条无增量，周末/盘前亦无可执行新edge，不以旧闻开空
不做 百时美施贵宝(BMS)（BMY.US）
Krazati对照落后的信息已随数据落地，无新增事实且占比有限，不构成新的做空或做多理由
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
STAT通讯重述罗氏divarasib头对头优于Lumakras/Krazati的三期数据，但顶线7月已公告、完整数据10-25 ESMO/NEJM已落地并被多源广泛传播，属于旧催化兑现后的回顾性文字，无新增事实且罗氏为超大盘药企、单一管线弹性小，不做。
🔎 新鲜度:最早出现 2026-07-02 · 扩散 high · price-in 风险 high ↗
主要风险
- 若罗氏后续基于该数据宣布FDA申报受理、获批或大型合作/授权，将构成新的状态迁移，需重新评估，本条通讯不含此类节点
反向证据
- 做多前查反向 · 来源 processed_events/web · 日期 2026-10-26 · 影响 none
本条及已有报道均未出现申报受理、获批、授权合作等新状态迁移，无新增正面催化
检索:divarasib FDA filing approval partnership 2026-10-26 - 做空前查反向 · 来源 processed_events · 日期 2026-10-26 · 影响 none
未见安全性恶化或数据被质疑的反证；竞争利空对AMGN/BMY亦为旧信息，不支持新开空
检索:divarasib safety concern NEJM rebuttal
先例如何影响了这次决策
对本次决策的影响:确认按NO_INCREMENTAL_FACT早停，不出任何腿
方向:无需新增先例：本条不构成新催化，前序对同一事件的多源决策（通稿/Fierce/Bloomberg/RTTNews/格隆汇）均判不做且理由一致
涨幅量级:不适用——无新增事实，不用先例校准幅度
形态:顶线(7月)→完整数据(10-25)→媒体回顾(10-26)呈现典型'数据落地后媒体重述'形态，属见光后扩散
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- fetch_decision_experience 成功 stock_tools_inprocess · 4 ms
{ - search_processed_events 成功 stock_tools HTTP · 1,330 ms
{"result": "search_processed_events:agent query=`divarasib second-line nsclc outperform lumakras krazati | roche divarasib kras g12c lung cancer esmo data | 罗氏 divarasib kras 抑制剂 esmo 临床数据`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 46.0/72 小时、3002 条本臂决策(完整)，返回 7 条候选。\n• 10-26 03:30 UTC(北京 11:30) [bm25:56%] 不做 AMGN.U
原文全文
展开原文 · 2,009 字
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
You’re reading our ESMO in 30 Seconds newsletter. Sign up here to get updates from future major European cancer conferences in your inbox.
We’ve made it. Here’s our last newsletter from this year’s European Society for Medical Oncology meeting. But before we bust out of this convention center for the final time, a reminder that we’ll be recapping ESMO on Thursday at 10 a.m. Eastern. Register for the virtual event here, and thanks very much for reading.
Advertisement
Roche gets a lung cancer win
One of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which inhibits G12C KRAS mutations, in second-line advanced non-small cell lung cancer, where it outpaced older KRAS inhibitors from Amgen and Bristol Myers Squibb.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Newsletter
Your morning rundown of the science, politics, and money driving biotech today
Please enter a valid email address.Sign Up
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
You’re reading our ESMO in 30 Seconds newsletter. Sign up here to get updates from future major European cancer conferences in your inbox.
We’ve made it. Here’s our last newsletter from this year’s European Society for Medical Oncology meeting. But before we bust out of this convention center for the final time, a reminder that we’ll be recapping ESMO on Thursday at 10 a.m. Eastern. Register for the virtual event here, and thanks very much for reading.
Advertisement
Roche gets a lung cancer win
One of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which inhibits G12C KRAS mutations, in second-line advanced non-small cell lung cancer, where it outpaced older KRAS inhibitors from Amgen and Bristol Myers Squibb.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Newsletter
Your morning rundown of the science, politics, and money driving biotech today
Please enter a valid email address.Sign Up
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
6b3bc80aac· 2026-10-27 17:12 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前